Drug or treatment

Patritumab clinical trials

• 6Clinical trials
• 32Countries

Newest trials

All recruiting trials (6)

• Patritumab deruxtecan for HR+/HER2- unresectable locally advanced or metastatic breast cancer

  This trial tests whether patritumab deruxtecan helps people with hormone receptor–positive, HER2‑negative advanced breast cancer who have progressed on CDK4/6 inhibitor plus endocrine therapy live longer or have slower cancer growth compared with standard chemotherapy.

  Recruiting at 203 sites Phase 3 Merck Sharp & Dohme LLC · Daphne, Alabama and 205 other locations · NCT07060807

• Patritumab deruxtecan for children with relapsed or refractory hepatoblastoma or rhabdomyosarcoma

  This trial tests an antibody-drug conjugate called HER3-DXd (patritumab deruxtecan) to see if it is safe and can shrink relapsed or treatment-resistant hepatoblastoma or rhabdomyosarcoma in children.

  Recruiting at 64 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 63 other locations · NCT06941272

• New treatment approach for high-risk early-stage breast cancer

  This study is testing a new combination of treatments for people with high-risk early-stage triple-negative breast cancer to see if it can shrink tumors more than the usual treatment before surgery.

  Recruiting at 17 sites Phase 2 Merck Sharp & Dohme LLC · Santa Monica, California and 16 other locations · NCT06797635

• Treatment of advanced HER2 positive breast cancer with patritumab deruxtecan and other agents

  This study is testing a new treatment combining patritumab deruxtecan with other cancer drugs to see if it helps people with advanced HER2 positive breast cancer that can't be surgically removed.

  Recruiting at 18 sites Phase 1/2 Merck Sharp & Dohme LLC · Aurora, Colorado and 17 other locations · NCT06686394

• Patritumab deruxtecan for solid tumors with NRG1 fusion

  This study is testing a new treatment called patritumab deruxtecan to see if it helps people with solid tumors that have a specific genetic change known as an NRG1 fusion.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT06383884

• Using PET/CT to Measure HER3 Levels in Lung Cancer Patients

  This study is testing a new imaging method to see how much of a specific protein called HER3 is in lung cancer patients who have already been treated, to help figure out who might benefit from a new drug.

  Recruiting Phase 2 The Netherlands Cancer Institute · Amsterdam, North Holland · NCT06222489

Quick answers

How many clinical trials of Patritumab are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 32 countries. The most sites are in South Korea (5 trials), United States (4 trials), Canada (3 trials), Israel (3 trials), Spain (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 1/2: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →